GlassScriptPhysician profile
Humdoon Choudhry
NPI 1861020950
$1,101.50
in general payments reported to CMS, 2019-2025
12 companies · $498 in 2025
The $498 reported for 2025 was more than what 79% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $282 · 2024: $322 · 2025: $498.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,102.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,101.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $244.08 | 2023-2025 | Fasenra |
| Glaxosmithkline, LLC. | $125.00 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $125.00 | 2024 | Takhzyro |
| Ionis Pharmaceuticals, INC. | $121.84 | 2025 | Dawnzera |
| Csl Behring | $120.42 | 2025 | Hizentra |
| Regeneron Healthcare Solutions, INC. | $119.71 | 2024 | |
| Amgen INC. | $102.00 | 2025 | |
| Linvatec Corporation | $60.71 | 2024 | Biobrace 23mm, Allograft Tissue, Colink Afx |
| Incyte Corporation | $31.18 | 2025 | Opzelura |
| Novo Nordisk INC | $18.60 | 2023 | Ozempic, Rybelsus |
| Exact Sciences Corporation | $16.68 | 2023 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.28 | 2024 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Humdoon Choudhry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.